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Introduction
Meningiomas are the most common primary intracranial 
tumors with an incidence of 6 cases per 100 000.1 
Intracranial tumors arise from meningothelial cells of the 
arachnoid membrane that surrounds the central nervous 
system. The resulted lesions are usually benign, slow-
growing, and circumscribed. Its main risk factors include 
ionizing radiation, and neurofibromatosis type 1 (NF1).2 
Prolactinomas represent the most common subtypes with 
25%-41% of total pituitary adenomas in adults.3 Regarding 
that according to the recent studies prevalence of hyper-
prolactinemia is increasing, special attention is paying to 
this type of tumor.4 
Several cases of meningioma developed after radiation 
therapy of pituitary adenomas are reported.5 However, the 
concomitant occurrence of these neoplasms is rare. In this 
regard, currently, six case report studies are published.6-9 
Considering the rarity of this co-morbidity, another case 
of simultaneous occurrence of frontal meningioma and 
prolactinoma is reported in the current study. As well, 
a discussion about the clinical presentation, imaging 
features and management of this rare condition is 
provided.
Case Presentation 
A 37 years old Asian woman presented at the out-patient 
clinic with an episode of amenorrhea, galactorrhea, and 
vaginal dryness (for the past 10 months). During the 
physical examination, there was no sign of neurological 
disorders. There was no abnormality in her medical 
records. She had two vaginal delivery without postpartum 
complications. Initial laboratory workups showed that all 
of her endocrinological hormones are in normal range 
except for hyperprolactinemia that was 2122 uUI/mL 
(normal range 102-496 uIU/mL). 
Moreover, MRI revealed a lesion of 2 x 2 mm in 
diameter at the posterior pituitary, T1W and T2W iso-
intense (Figure 1), and an extra-axial lesion of 14 x 9 
mm with a dural tail sign, T1W iso-intense, T2W hypo-
intense, homogeneous enhancement on T1 Gd located 
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Abstract
Instruction: The current study reports a woman with pituitary adenoma and frontal convexity 
meningioma that was detected accidentally. To the best of our knowledge, this case is considered 
as a rare clinical scenario. 
Case Presentation: A 37 years old woman suffering from amenorrhea and galactorrhea had her 
detail investigation showed hyperprolactinemia. The patient was diagnosed with a prolactinoma, 
and a frontal convexity meningioma was discovered on magnetic resonance imaging (MRI). The 
prolactinoma controlled with Bromocriptine therapy, while the meningioma monitored through 
medical observation. After two months of pharmaceutical medication, her symptoms improved with 
the decrease in serum prolactin. 
Conclusion: Thanks to sophisticated MRI techniques, meningioma and prolactinoma were 
incidentally detected. It should be noted that co-morbidity of prolactinoma and meningioma is 
very rare. The mechanism of the association between these two familiar types of intracranial tumors 
has not yet been clarified, which indicates the need for further studies to offer possible targeted 
treatment for patients. 
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at the right frontal lobe (Figure 2). Diagnostic processes 
revealed that the patient had both a prolactinoma and a 
right convexity meningioma.
The prolactinoma was managed with pharmaceutical 
medication. The medication began with oral 
Bromocriptine (Parlodel®) 2.5 mg with 1 tablet daily 
for 2 months. To treat convexity meningioma, due to 
the size and asymptomatic condition, surgery was not 
recommended. After 2 months of treatment, the dose of 
serum prolactin decreased to 1535 uUI/mL. Menstrual 
cycles and sexual functions were normalized. As well, 
galactorrhea also decreased. Monthly follow-ups, 
including serum prolactin test, are necessary. The dosage 
of oral Bromocriptine would be adjusted in accordance 
with serum prolactin. Meanwhile, the meningioma was 
monitored by using clinical symptoms. To Monitor the 
progression of both tumors, MRI would be performed 6 
months after the initial observation.
 
Discussion
The simultaneous occurrence of meningioma and 
prolactinoma is rare. The authors could find six studies 
that were related to this area (Table 1), which all were 
reviewed. Both males and females were investigated by 
these studies. Also, meningiomas were located in different 
locations.
Fortuitously, the results of the MRI that was performed 
to diagnosis prolactinomas revealed several meningiomas. 
Technically, histological examination should be 
performed to confirm the diagnosis of meningiomas. 
However, signal characteristics obtained from the MRI 
images (dura tail sign, T1W iso-intense, T2W hypo-
intense, homogeneous enhancement on T1 Gd) (Figure 
2) were acceptable. Therefore, versatile imaging technique 
such as MRI would be helpful, particularly for diagnostic 
procedures of concomitant intracranial lesions.
There are three possible reasons to explain pituitary 
adenomas associated with meningioma, including: by 
chance occurrence, the impact of environmental factors, 
or genetic predisposition. Currently, the exact association 
between meningioma and pituitary adenoma has not 
been elucidated.10
Recent studies reported that prolactin stimulates the 
proliferation of human meningioma cells in vitro, and a 
possible impact of prolactin in the growth of meningioma 
is suggested.11,12 Also, there are studies that reviewed 
meningiomas cases which were developed after radiation.13 
Since there was no history of radiation or familial-related 
diseases in the present patient, the occurrence of these 
two intracranial tumors may be coincidental. However, 
the possibility of meningioma caused by high levels of 
serum prolactin should not be ignored, because human 
meningiomas express functional receptors for prolactin 
which are involved in mediating its proliferative effect.12
To manage meningioma, the Endocrine Society 
Clinical Practice Guideline recommended administration 
of dopamine agonist in patients with pituitary 
microadenomas (prolactinoma) who have amenorrhea.14 
Our patient had her follow-up after 2 months of using 
Bromocriptine with the resolution of previous symptoms 
and a decrease in serum prolactin, from 2122 uUI/mL to 
1535 uUI/mL. Regarding that the patient well-responded 
to Bromocriptine therapy, surgical treatment is not 
recommended. Concerning the meningioma, according 
to EANO guidelines, since there was no mass effect and 
symptoms, observational management was chosen.15 The 
exact association between prolactinoma and meningioma 
was not proposed due to the rarity of this co-morbidity. 
Figure 1. Left: The parenchyma of the pituitary gland, below 
the pituitary pedicle, has a lesion 2 x 2 mm in diameter at the 
posterior pituitary, slight restricted diffusion is seen on T1W 
dynamic. Right: The parenchyma of the pituitary gland on T1W 
and T2W iso-intense on post-contrast study (white arrow).
Figure 2. Left: postcontrast axial T1-weighted MR Image of the 
brain demonstrating an anterior parasagittal meningioma located 
at the right frontal lobe. Right: postcontrast sagittal T1-weighted 
MR Image an extra-axial lesion in 14 x 9 mm with dural tail sign 
T1W iso-intense, T2W hypo-intense homogeneous enhancement 
in T1 Gd (white arrow).
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Instead of applying specific targeted treatment for both 
tumors, decisions regarding the treatment of the patient 
were made separately depending on each tumor clinical 
manifestation. However, a study in 1997 suggested 
new therapeutic strategies such as prolactin-receptor 
antagonist.12 Therefore, further studies are required to 
specify the management protocol for patients with these 
two types of intracranial tumors. Follow-up care involves 
monthly serum prolactin measurement. In addition, MRI 
should be performed 6 months after the initial treatment 
to re-evaluate both tumors.15
Conclusion
Thanks to sophisticated MRI techniques, meningioma 
and prolactinoma were incidentally detected. Clinical 
monitoring for each tumor was applied separately, 
because the association between these two types of 
intracranial tumors were not clarified, which indicate the 
need for further studies to propose targeted treatment for 
such patients.
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Table 1. Summary of Reported Cases in the Literature
No. Study Sex Age Pituitary Adenoma Meningioma Site Management
1 Zentner et al8 M 46 Prolactinoma Planum sphenoidale Resection 
2 Görge et al9 M 53 Prolactinoma Para- and suprasellar Resection
3 Abs et al6 F 47 Prolactinoma Tuberculum sellae Resection
4 Abs et al6 F 45 Prolactinoma Temporal fossa No surgery
5 Abs et al6 F 61 Prolactinoma Choroid plexus No surgery
6 Amirjamshidi et al7 F 37 Prolactinoma Suprasellar Resection
7 Present case F 37 Prolactinoma Frontal convexity No surgery
